Researchers aimed to explore the effect of Tα1 in the gut, using both Tα1 and the pharmaceutical formulation Zadaxin® in two different murine experimental models:1. Model of high fat diet-induced intestinal inflammation, dysbiosis and pancreatic dysfunction, to define the efficacy of Tα1 in a model of “leaky gut”. 2. Model of gastrointestinal infection with C. albicans in CftrF508del mice and Ido1-/- mice. Their results indicated that Tα1 as well Zadaxin are able to ameliorate inflammation and promote barrier function in the gut of CftrF508del, and this effect appears to be IDO1-dependent. In regard to the objective to show the thymosin effect in rescuing CFTR-F508del activity in the same animal models, studies are in progress. The final aim is to repurpose thymosin, a drug in use for different indications, in the field of CF therapies.